The Biostatistics and Data Management Core (BDMC Core B) of the MPD Research Consortium (MPD-RC) provides, statistical collaboration and data rnanagement and operations, support for .MPD-RC investigator initiated research and clinical projects through the combined expertises of the integrated Cores at NYU School of.Medicine (Judith D. Goldberg,Sc.D.) and the Consorzio Mario Negri Sud (Robterto Marchioli, M.D.). The collaboration allpvys .the integration of alMaboratpry.and clinjcal study data into the MPD-RC central database for integ rated, statistical analysis. In particular, state of the art statistical collaboration is provided forthe design, conduct, and analysis of translational research including clinical trials and laboratory studies to further the understanding of the causes and treatment of myelofibrosis and polycythemia vera. The Data Management component of the Core provides on line database and data entry systems and procedures and an infrastructure to facilitate communication among investigators and to facilitate the conduct of multicenter clinical and translational studies in these disease.
The Biostatistics and Data Management Core of the MPD-RC provides collaboration in all phases of the research projects from study design through reporting to obtain meanlngful results from the multiple MPDRC research projects and programs using minimal patieint and animal resources. The user friendly web-based data management system facilitates data collection and management and collaborations across an international network of investigators conducting multicenter clinical trials and research programs.
|Peeken, Jan C; Jutzi, Jonas S; Wehrle, Julius et al. (2018) Epigenetic regulation of NFE2 overexpression in myeloproliferative neoplasms. Blood 131:2065-2073|
|Wang, Xiaoli; Hu, Cing Siang; Petersen, Bruce et al. (2018) Imetelstat, a telomerase inhibitor, is capable of depleting myelofibrosis stem and progenitor cells. Blood Adv 2:2378-2388|
|Zimran, Eran; Tripodi, Joseph; Rampal, Raajit et al. (2018) Genomic characterization of spleens in patients with myelofibrosis. Haematologica 103:e446-e449|
|Kleppe, Maria; Koche, Richard; Zou, Lihua et al. (2018) Dual Targeting of Oncogenic Activation and Inflammatory Signaling Increases Therapeutic Efficacy in Myeloproliferative Neoplasms. Cancer Cell 33:785-787|
|Qiu, Jiajing; Salama, Mohamed E; Hu, Cing Siang et al. (2018) The characteristics of vessel lining cells in normal spleens and their role in the pathobiology of myelofibrosis. Blood Adv 2:1130-1145|
|Pronier, Elodie; Cifani, Paolo; Merlinsky, Tiffany R et al. (2018) Targeting the CALR interactome in myeloproliferative neoplasms. JCI Insight 3:|
|Migliaccio, Anna Rita (2018) A vicious interplay between genetic and environmental insults in the etiology of blood cancers. Exp Hematol 59:9-13|
|Gupta, Vikas; Kosiorek, Heidi E; Mead, Adam et al. (2018) Ruxolitinib Therapy Followed by Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation for Myelofibrosis: Myeloproliferative Disorders Research Consortium 114 Study. Biol Blood Marrow Transplant :|
|Gnanapragasam, Merlin Nithya; Crispino, John D; Ali, Abdullah M et al. (2018) Survey and evaluation of mutations in the human KLF1 transcription unit. Sci Rep 8:6587|
|Migliaccio, Anna Rita; Varricchio, Lilian (2018) Concise Review: Advanced Cell Culture Models for Diamond Blackfan Anemia and Other Erythroid Disorders. Stem Cells 36:172-179|
Showing the most recent 10 out of 195 publications